Personalized accelerated physiologic pacing.

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Research

Background:

• Heart failure with preserved ejection fraction (HFpEF) is a growing concern with significant socioeconomic impact.
• Current recommendations for HFpEF often involve pharmacological heart rate lowering to improve ventricular filling.
• Beta-blocker overprescription in HFpEF, even with comorbidities like atrial fibrillation or coronary artery disease, may have adverse effects.

Purpose of the Study:

• To challenge the prevailing paradigm of heart rate lowering in HFpEF.
• To explore the potential hemodynamic and structural benefits of faster heart rates in HFpEF.
• To introduce conduction system pacing as a safe therapeutic strategy for HFpEF.

Main Methods:

• Review of existing literature and clinical observations regarding heart rate management in HFpEF.
• Discussion of the physiological basis for accelerated pacing, including effects on cardiac filling pressures and ventricular capacitance.
• Reference to the myPACE randomized controlled trial as a proof-of-concept study.

Main Results:

• Faster heart rates may offer hemodynamic and structural advantages in HFpEF, contrary to established beliefs.
• Conduction system pacing can safely achieve accelerated cardiac excitation.
• The myPACE trial provides initial evidence for this novel therapeutic approach.

Conclusions:

• The traditional approach of lowering heart rate in HFpEF may be misguided.
• Accelerated pacing via conduction system pacing presents a promising alternative for managing HFpEF.
• Further research and clinical application of this pacing strategy are warranted.